Abstract:Type 2 diabetes (T2D) mellitus has emerged as a major global health concern that has accelerated in recent years due to poor diet and lifestyle. Afflicted individuals have high blood glucose levels that stem from the inability of the pancreas to make enough insulin to meet demand. Although medication can help to maintain normal blood glucose levels in individuals with chronic disease, many of these medicines are outdated, have severe side effects, and often become less efficacious over time, necessitating the need for insulin therapy. G protein–coupled receptors (GPCRs) regulate many physiologic processes, including blood glucose levels. In pancreatic β cells, GPCRs regulate β -cell growth, apoptosis, and insulin secretion, which are all critical in maintaining sufficient β -cell mass and insulin output to ensure euglycemia. In recent years, new insights into the signaling of incretin receptors and other GPCRs have underscored the potential of these receptors as desirable targets in the treatment of diabetes. The signaling of these receptors is modulated by GPCR kinases (GRKs) that phosphorylate agonist-activated GPCRs, marking the receptor for arrestin binding and internalization. Interestingly, genome-wide association studies using diabetic patient cohorts link the GRKs and arrestins with T2D. Moreover, recent reports show that GRKs and arrestins expressed in the β cell serve a critical role in the regulation of β -cell function, including β -cell growth and insulin secretion in both GPCR-dependent and -independent pathways. In this review, we describe recent insights into GPCR signaling and the importance of GRK function in modulating β -cell physiology. Significance Statement Pancreatic β cells contain a diverse array of G protein–coupled receptors (GPCRs) that have been shown to improve β -cell function and survival, yet only a handful have been successfully targeted in the treatment of diabetes. This review discusses recent advances in our understanding of β -cell GPCR pharmacology and regulation by GPCR kinases while also highlighting the necessity of investigating islet-enriched GPCRs that have largely been unexplored to unveil novel treatment strategies.

Β-Arrestins: Multifunctional Signaling Adaptors in Type 2 Diabetes.

Progress in the Study of Β-Arrestins in Glucose and Lipid Metabolism

Phospho-selective Mechanisms of Arrestin Conformations and Functions Revealed by Unnatural Amino Acid Incorporation and 19F-NMR

The role and mechanism of β-arrestin2 in signal transduction

Involvement of Β-Arrestins in Cancer Progression

Insight into the regulatory mechanism of β-arrestin2 and its emerging role in diseases

Β-Arrestin Signaling and Regulation of Transcription

Functional Specialization of Β-Arrestin Interactions Revealed by Proteomic Analysis

Β-Arrestins As Potential Therapeutic Targets for Alzheimer’s Disease

β -Arrestins promote podocyte injury by inhibition of autophagy in diabetic nephropathy

Classical and new roles of β-arrestins in the regulation of G-PROTEIN-COUPLED receptors

Deficiency of a β-arrestin-2 signal complex contributes to insulin resistance

β-Arrestins 1 and 2 are critical regulators of inflammation

Distinct Conformations of GPCR–β-arrestin Complexes Mediate Desensitization, Signaling, and Endocytosis

β-arrestin2: an emerging player and potential therapeutic target in inflammatory immune diseases

The multifaceted functions of β-arrestins and their therapeutic potential in neurodegenerative diseases

Roles of Β-Arrestins in Signaling Pathway of AT1 Receptor

β-Arrestin Recruitment and Biased Agonism at Free Fatty Acid Receptor 1

Loss of Β-Arrestin2 Mediates Pancreatic-Islet Dysfunction in Mice

β-arrestin and β-adrenergic Receptor

The Role of G Protein-Coupled Receptors and Receptor Kinases in Pancreatic {beta}-Cell Function and Diabetes